GSK plc ADR Stock
GSK plc ADR Stock
We can see a decrease in the price for GSK plc ADR. Compared to yesterday it has lost -€0.600 (-1.290%).
So far the community has only identified positive things for GSK plc ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of GSK plc ADR in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc ADR | -1.290% | 2.727% | -2.165% | 39.506% | 8.134% | 40.373% | 6.353% |
| Bayer AG ADR | 1.720% | 1.754% | -4.918% | 69.343% | 31.818% | -10.078% | -6.452% |
| Novartis AG | -0.700% | 0.307% | 0.234% | 34.246% | 16.162% | 71.600% | 71.600% |
| Novartis AG ADR | -0.720% | 0.000% | 0.000% | 34.634% | 16.456% | 45.877% | 76.923% |
Comments
GSK (GSK) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Show more
Ratings data for GSK provided by MarketBeat
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
Show more
Ratings data for GSK provided by MarketBeat
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Show more
Ratings data for GSK provided by MarketBeat